Histomorphology has been a mainstay of cancer diagnosis in anatomic pathology for many
years. DNA methylation profiling is an additional emerging tool that will serve as an adjunct …

The management of advanced-stage renal cell carcinoma (RCC) has been transformed by
the development of immune-checkpoint inhibitors (ICIs). Nonetheless, most patients do not …

Mutations in fumarate hydratase (FH) cause hereditary leiomyomatosis and renal cell
carcinoma. Loss of FH in the kidney elicits several oncogenic signalling cascades through …

Clear cell renal cell carcinomas (ccRCCs) represent∼ 75% of RCC cases and account for
most RCC-associated deaths. Inter-and intratumoral heterogeneity (ITH) results in varying …

Immune checkpoint blockade (ICB) results in durable disease control in a subset of patients
with advanced renal cell carcinoma (RCC), but mechanisms driving resistance are poorly …

Gains and losses of DNA are prevalent in cancer and emerge as a consequence of inter-
related processes of replication stress, mitotic errors, spindle multipolarity and breakage …

Aneuploidies—whole-chromosome or whole-arm imbalances—are the most prevalent
alteration in cancer genomes,. However, it is still debated whether their prevalence is due to …

Artificial intelligence (AI) can extract visual information from histopathological slides and
yield biological insight and clinical biomarkers. Whole slide images are cut into thousands of …

Diverse subtypes of renal cell carcinomas (RCCs) display a wide spectrum of
histomorphologies, proteogenomic alterations, immune cell infiltration patterns, and clinical …

The therapeutic algorithm of renal cell carcinoma has been revolutionized by the approval of
immunotherapy agents by regulatory agencies. However, objective and durable responses …